Effects of AMPA/kainate glutamate receptor antagonists on cocaine- induced convulsions and lethality in mice

European Journal of Pharmacology

Volumn 386, Issue 2-3, 1999, Pages 181-186

  Pouw, Buddy ^a   Nour, May ^a   Matsumoto, Rae R ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF PHARMACY   (United States)

Author keywords

AMPA receptor; Cocaine; Convulsion; Kainate receptor; NMDA receptor; Toxicity

Indexed keywords

1 (4 AMINOPHENYL) 4 METHYL 7,8 METHYLENEDIOXY 5H 2,3 BENZODIAZEPINE; 5 CHLORO 7 TRIFLUOROMETHYL 2,3 QUINOXALINEDIONE; 6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; 6,7 DICHLORO 5 NITRO 2,3 QUINOXALINEDIONE; AMPA RECEPTOR ANTAGONIST; COCAINE; DIMETHYL SULFOXIDE; GLUTAMATE RECEPTOR ANTAGONIST; GLYCINE RECEPTOR ANTAGONIST; IONOTROPIC RECEPTOR; KAINIC ACID RECEPTOR ANTAGONIST; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CONVULSION; DRUG EFFECT; DRUG OVERDOSE; DRUG POTENTIATION; LETHALITY; MALE; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

ANIMALS; ANTI-ANXIETY AGENTS; BENZODIAZEPINES; COCAINE; DRUG THERAPY, COMBINATION; EXCITATORY AMINO ACID ANTAGONISTS; MALE; MICE; QUINOXALINES; RECEPTORS, AMPA; RECEPTORS, KAINIC ACID; SEIZURES;

EID: 0033401714     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00740-2     Document Type: Article

References (56)

1. Aylwin M.L., Horowitz J.M., Bonham A.C. NMDA receptors contribute to primary visceral afferent transmission in the nucleus of solitary tract. J. Neurophysiol. 77:1997;2539-2548.
2. Bagetta G., Iannone M., Palma E., Nistico G., Dolly J.O. N-methyl-D-aspartate and non-N-methyl-D-aspartate receptors mediate seizures and CA1 hippocampal damage induced by dendrotoxin-K in rats. Neuroscience. 71:1996;613-624.
3. Bekkers J.M., Stevens C.F. NMDA and non-NMDA receptors are co-localized at individual excitatory synapses in cultured rat hippocampus. Nature. 341:1989;230-233.
4. Bleakman R., Schoep D.D., Ballyk B., Bufton H., Sharpe E.F., Thomas K., Ornstein P.L., Kamboj R.K. Pharmacological discrimination of GluR5 and GluR6 kainate receptor subtypes by (3S, 4aR, 6R, 8aR)-6-[2-1(2) H-tetrazole-5-yl)ethyl]decadhydroisoquinoline-3-carboxylic acid. Mol. Pharmacol. 49:1996;581-585.
5. Bongianni F., Mutolo D., Carfi M., Pantaleo T. Area postrema glutamate receptors mediate respiratory and gastric responses in the rabbit. NeuroReport. 9:1998;2057-2062.
6. Cervo L., Samanin R. Effects of dopaminergic and glutamatergic receptor antagonists on the acquisition and expression of cocaine conditioning place preference. Brain Res. 673:1995;242-250.
7. Chapman A.G., Smith S.E., Meldrum B.S. The anticonvulsant effect of the non-NMDA antagonists, NBQX and GYKI 52466, in mice. Epilepsy Res. 9:1991;92-96.
8. Collingridge G.L., Singer W. Excitatory amino acid receptors and synaptic plasticity. Trends Pharmacol. Sci. 11:1990;290-296.
9. Desce J.M., Godeheu G., Galli T., Artaud F., Cheramy A., Glowinski J. L-Glutamate-evoked release of dopamine from synaptosomes of the rat striatum: involvement of N-methyl-D-aspartate receptors. Neuroscience. 47:1992;333-339.
10. Durmuller N., Graggs M., Meldrum B.S. The effect of the non-NMDA receptor antagonists GYKI 52466 and NBQX and the competitive NMDA receptor antagonist D-CPPene on the development of amygdala kindling and on amygdala-kindled seizures. Epilepsy Res. 17:1994;167-174.
11. Fedele E., Raiteri M. Desensitization of AMPA receptors and AMPA-NMDA receptor interaction: an in vivo cyclic GMP microdialysis study in rat cerebellum. Br. J. Pharmacol. 117:1996;1133-1138.
12. Itzhak Y., Ali S.F. Effect of ibogaine on the various sites of the NMDA receptor complex and sigma binding sites in rat brain. Ann. N. Y. Acad. Sci. 844:1998;245-251.
13. Itzhak Y., Stein R. Sensitization to the toxic effects of cocaine in mice is associated with the regulation of N-methyl-D-aspartate receptors in the cortex. J. Pharmacol. Exp. Ther. 262:1992;464-470.
14. Jackson A., Mead A.N., Rocha B.A., Stephens D.N. AMPA receptors and motivation for drug: effect of the selective antagonist NBQX on behavioural sensitization and on self-administration in mice. Behav. Pharmacol. 9:1998;457-467.
15. Karler R., Calder L.D., Thai L.H., Bedinfield J.B. Cocaine behavioral sensitization and the excitatory amino acids. Psychopharmacology. 115:1994;305-310.
16. Kohama S.G., Garyfallou V.T., Urbanski H.F. Regional distribution of glutamate receptor mRNA in the monkey hippocampus and temperal cortex: influence of estradiol. Brain Res. 53:1998;328-332.
17. Lallement G., Delamanche I.S., Fernot-Marino I., Baubichon D., Denoyer M., Carpentier P., Blanchet G. Neuroprotective activity of glutamate receptor antagonists against soman-induced hippocampal damage: quantification with an omega-3 site ligand. Eur. J. Pharmacol. 618:1993;227-237.
18. Lee H., Choi B.H. Density and distribution of excitatory amino acid receptors in the developing human fetal brain: a quantitative anteroradiographic study. Exp. Neurol. 118:1992;284-290.
19. Li Y., Vartanian A.J., White F.J., Xue C.J., Wolf M.E. Effects of the AMPA receptor antagonist NBQX on the development and expression of behavioral sensitization to cocaine and amphetamine. Psychopharmacology. 134:1997;266-276.
20. Lippert K., Welsch M., Krieglstein J. Over-additive protective effect of dizocilpine and NBQX against neuronal damage. Eur. J. Pharmacol. 253:1994;207-213.
21. 2+ influx in oligodendrocyte progenitors. Eur. J. Pharmacol. 338:1997;277-287.
22. Löscher W. Pharmacology of glutamate receptor antagonists in the kindling model of epilepsy. Prog. Neurobiol. 54:1998;721-741.
23. Löscher W., Honack D. Effects of the non-NMDA antagonists NBQX and the 2,3-benzodiazepine GYKI 52466 on different seizure types on mice: comparison with diazepam and interactions with flumazenil. Br. J. Pharmacol. 113:1994;1349-1357.
24. Maj J., Rogoz Z., Skuza G., Jaros T. Some behavioral effects of CNQX and NBQX, AMPA receptor antagonists. Pol. J. Pharmacol. 47:1995;269-277.
25. Mash D.C., Staley J.K., Pablo J.P., Holohean A.M., Hackman J.C., Davidoff R.A. Properties of ibogaine and its principal metabolite (12-hydroxyibogamine) at the MK-801 binding site of the NMDA receptor complex. Neurosci. Lett. 192:1995;53-56.
26. Matsumoto R.R., Brackett R.L., Kanthasamy A.G. Novel NMDA/glycine site antagonists attenuate cocaine-induced behavioral toxicity. Eur. J. Pharmacol. 338:1997;233-242.
27. Matsumoto R.R., Brackett R.L., Pouw B., Blyden J.F. Prevention of cocaine-induced behavioral toxicity by NMDA/glycine site and competitive antagonists. Soc. Neurosci. Abstr. 24:1998;311.9.
28. McCracken K.A., Bowen W.D., de Costa B.R., Matsumoto R.R. Two novel σ ligands, BD1047 and LR172, attenuate cocaine-induced convulsions and locomotor activity. Eur. J. Pharmacol. 370:1999;225-232.
29. McGinty J.F. Introduction to the role of excitatory amino acids in the actions of abused drugs: a symposium presented at the 1993 annual meeting of the College on Problems of Drug Dependence. Drug Alcohol Depend. 37:1995;91-94.
30. Miyawaki T., Minson J., Arnolda L., Chalmers J. Role of excitatory amino acid receptors in cardiorespiratory coupling in ventrolateral medulla. Am. J. Physiol. 271:1996;R1221-R1230.
31. Monaghan D.T., Bridges R.J., Cotman C.W. The excitatory amino acid receptors: their classes, pharmacology, and distinct properties in the function of the central nervous system. Annu. Rev. Pharmacol. Toxicol. 29:1989;365-402.
32. Moore L.E., Buchanan J.T., Murphey C.R. Localization and interaction of N-methyl-D-aspartate and non-N-methyl-D-aspartate receptors of lamprey spinal neurons. Biophys. J. 68:1995;96-103.
33. Ohno K., Okada M., Tsutsumi R., Matsumoto N., Yamaguchi T. Characterization of cyclothiazide-enhanced kainate excitotoxicity in rat hippocampal cultures. Neurochem. Int. 32:1998;265-271.
34. Pouw B., Brown M., Matsumoto R.R. Non-NMDA antagonists fail to prevent cocaine-induced convulsions and lethality in mice. Soc. Neurosci. Abstr. 24:1998;191.8.
35. Pulvirenti L., Maldonado R., Koob G.F. NMDA receptors in the nucleus accumbens modulate intravenous cocaine, but not heroin self-administration in the rat. Brain Res. 594:1992;327-330.
36. Pulvirenti L., Berrier M., Koob G.F. Modulation of locomotor activity at the NMDA receptors in the nucleus accumbens core and shell regions of the rat. Brain Res. 664:1994;231-236.
37. Pulvirenti L., Balducci C., Koob G.F. Dextromethorphan reduces intravenous cocaine self-administration in the rat. Eur. J. Pharmacol. 321:1997;283-297.
38. Raiteri M., Garrone B., Pittaluga A. N-methyl-D-aspartic acid (NMDA) and non-NMDA receptors regulating hippocampal norepinephrine release: II. Evidence for functional cooperation and for coexistence on the same axon terminal. J. Pharmacol. Exp. Ther. 260:1992;238-242.
39. Rice A.C., DeLorenzo R.J. NMDA receptor activation during status epilepticus is required for the development of epilepsy. Brain Res. 782:1998;240-247.
40. Ritz M.C., George F.R. Cocaine-induced convulsions: pharmacological antagonism at serotonergic, muscarinic and sigma receptors. Psychopharmacology. 129:1997;299-310.
41. Rockhold R.W., Oden G., Ho I.K., Andrew M., Farley J.M. Glutamate receptor antagonists block cocaine-induced convulsions and death. Brain Res. Bull. 27:1991;721-723.
42. Rogawski M.A. Therapeutic potential of excitatory amino acid antagonists: channel blockers and 2,3-benzodiazepine. Trends Pharmacol. Sci. 14:1993;325-331.
43. Sheardown M.J., Nielsen E.O., Hansen A.J., Jacobsen P., Honore T. 2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline: a neuroprotectant for cerebral ischemia. Science. 247:1990;571-574.
44. Shimizu-Sasamata M., Kawasaki-Yatsugi S., Okaka M., Sakamoto S., Yatsugi S., Togami J., Hatanaka K., Ohmori J., Koshiya K., Usuda S., Murase K. YM90K: Pharmacological characterization as a selective and potent alpha-amino-3-hydroxy-5-methylisoxazole-4-proprionate/kainate receptor antagonist. J. Pharmacol. Exp. Ther. 276:1996;84-92.
45. Smith S.E., Durmuller M., Meldrum B.S. The non-N-methyl-D-aspartate receptor antagonists, GYKI 52644 and NBQX are anticonvulsant in two animal models of reflex epilepsy. Eur. J. Pharmacol. 201:1991;179-183.
46. Stefani A., Chen Q., Flores-Hernandez J., Jian Y., Reiner A., Surmeler D.J. Physiological and molecular properties of AMPA/kainate receptors expressed by striatal medium spiny neurons. Dev. Neurosci. 20:1998;242-252.
47. Taylor C.P., Vartanian M.G. Probenecid pretreatment enhances anticonvulsant action of NBQX in mice. Eur. J. Pharmacol. 213:1992;151-153.
48. Turski L., Jacobsen P., Honore T., Stephens D.N. Relief of experimental spasticity and anxiolytic/anticonvulsant actions of the alpha-amin-3-hydroxy-5-methyl-4-isoxazolepropionate antagonist 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline. J. Pharmacol. Exp. Ther. 260:1992;742-747.
49. Ushijima I., Kobayashi T., Suetsugi M., Watanabe K., Yamada M., Yamaguchi K. Cocaine: evidence for NMDA-, beta-carboline- and dopaminergic-mediated seizures in mice. Brain Res. 797:1998;347-350.
50. Witkin J.M., Tortella F.C. Modulation of N-methyl-D-aspartate protect against diazepam or phenobarbital-resistant cocaine convulsions. Life Sci. 48:1991;PL51-PL56.
51. Woodward R.M., Huettner J.E., Tran M., Guastella J., Keana J.F.W., Weber E. Pharmacology of 5-chloro-7-trifluoromethyl-1,4-dihydro-2,3-quinoxalinedione: a novel systemically active ionotropic glutamate receptor antagonist. J. Pharmacol. Exp. Ther. 275:1995;1209-1218.
52. Woodward R.M., Huettner J.E., Guastella J., Keana J.F.W., Weber E. In vitro pharmacology of ACEA-1021 and ACEA-1031: systemically active quinoxalinediones with high affinity and selectivity for N-methyl-D-aspartate receptor glycine sites. Mol. Pharmacol. 47:1995;568-581.
53. Yamaguchi S.I., Donevan S.D., Rogawski M.A. Anticonvulsant activity of AMPA/kainate antagonists: comparison of GYKI 52466 and NBQX in maximal electroshock and chemoconvulsant seizure models. Epilepsy Res. 15:1993;179-184.
54. Yu W., Miller R.F. The mechanism by which NBQX enhances NMDA currents in retinal ganglion cells. Brain Res. 709:1996;184-196.
55. Zarnowski T., Kleinrok Z., Turski W.A., Czuczawar S.J. 2,3-Dihydroxy-6-nitro-7-sulfamoylbenzo(f)quinoxaline enhances the protective ability of common anti-epileptic drugs against maximal electroshock-induced seizures in mice. Neuropharmacology. 32:1993;895-900.
56. Zormuski C.F., Yamada K.A., Price M.T., Olney J.W. A benzodiazepine recognition site associated with the non-NMDA glutamate receptor. Neuron. 10:1993;61-67.